Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma - GBI Research Reports

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma - GBI Research Reports
Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
Published Feb 01, 2010
89 pages — Published Feb 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research 'Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma', which provides insights into the unmet needs in the pharmaceutical and healthcare market and potential segments where RNA therapies can prove to be useful. This pharma report also delves deep into the market potential that RNA therapies hold in the future. Further, it provides insights into the R&D pipeline and the promising drugs. The study elucidates the current competitive landscape of the RNA therapeutics market. Finally, the report deals with key trend analysis on mergers and acquisitions, and licensing agreements involving RNA therapies.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Detailed market characterization including evaluation of market potential, annual cost of therapy and treatment usage patterns - Key technologies that have created significant impact on research and development of RNA therapeutics - Key factors that can drive the RNA therapeutics market potential - Key risks and issues associated with various RNA therapies- Competitive landscape of RNA therapeutics market. The key companies studied in this report are Antisense Pharma GmbH, Lorus Therapeutics, Isis Pharmaceuticals, Alfacell Corporation, Genta Incorporated, Atlantic Healthcare, Alnylam, OPKO, Oxford BioMedica, Dicerna Pharmaceuticals, Silence Therapeutics plc, Cequent Pharmaceuticals, Inc and Santaris Pharma.- Key M&A activities and licensing agreements that have taken place between 2008 and 2009 in the RNA therapeutics market.Reasons to buyThe report will aid business development and marketing executives in strategizing their product launches and help venture capitalists to identify promising small and medium sized enterprises. It will allow you to- Build effective strategies to launch pipeline products by identifying potential geographies - Exploit in-licensing and out-licensing opportunities by identifying products that will fill the portfolio gaps - Develop key strategic initiatives by studying the key strategies of top competitors - Identify potential SME companies that hold a lot of promise - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

  
Source:
Document ID
GBIHC018MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
GBIHC018MR - Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma189
1 Table of Contents35
1.1 List of Tables61
1.2 List of Figures71
2 RNA Therapeutics: Introduction81
2.1 GBI Research Report Guidance81
3 RNA Therapeutics Introduction to Ribonucleic Acid (RNA)93
3.1 What is RNA Therapy?91
3.1.1 RNA is the Key for Protein Synthesis91
3.1.1.1 Amino Acid Synthesis91
3.1.1.2 Transcription91
3.1.1.3 Translation91
Blocking Translation of mRNA Inhibits Protein Biosynthesis, the Key for Cell Proliferation101
3.3 Role of RNA in Pharmaceutical Industry101
3.3.1 Upstream Action of RNA Therapies Make them more effective Than the Existing Biologic Therapies101
3.3.1.1 Upstream Mechanism of Action111
3.3.1.2 Potential to act through natural pathway111
3.3.1.3 Potential to Target any Protein111
3.3.1.4 Reduced Time for Developing Therapies111
4 RNA Therapeutics Overview on RNA Technology1212
4.1 Antisense RNA121
4.1.1 Therapeutic Objective121
4.1.2 Issues with Antisense RNA Therapy121
4.1.2.1 Antisense RNA Therapies Are Susceptible to Nuclease Enzymes That Are Present Through Out the Body121
Naked Antisense RNA Therapies Have Poor Penetration Rates and Therefore, Fail to Display Desired Efficacy Levels131
4.1.2.3 Effective Delivery Systems That Can Mask Antisense RNA Therapies and Deliver Them to the Site of Action Are the Key131
Solutions Developed to Overcome Issues141
4.1.3.1 New Drug Delivery Technologies Are Being Adopted to Effectively Delivery Antisense RNA Therapies at the Desired Cell141
4.1.3.2 Synthetic Antisense Oligonucleotides Are Resistant to RNA Nucleases and They Display Better Efficacy Results than Normal Antisense Oligonucleotides141
4.2 RNA Interference Technology151
4.2.1 siRNA151
4.2.1.1 Therapeutic Objective151
4.2.2 Micro RNA161
4.2.2.1 Therapeutic Objective161
4.2.3 Issues with Interfering RNA Therapy171
4.2.3.1 Similar to Antisense RNA Therapies, Naked siRNA Therapies Too Are Vulnerable to Serum Nucleases171
4.2.3.2 RNA Interference Therapies Sometimes Activate Interferon Responses 181
4.2.3.3 The Degradation by Serum Nucleases and Lack of Effective Delivery Systems Are Restraining RNAi Therapies from Proving Their Efficacy and Safety Profiles181
4.2.4 Soultions Developed to Overcome Issues191
4.2.4.1 Redesigning is One of the successful means to Develop Therapies That Can Effectively induce Gene Suppression through RNA interference Pathway191
4.2.4.2 Drug Delivery Technologies, Both Viral and Non-viral, That Can Deliver RNAi Therapies at The site of Action Are in Requirement192
4.2.4.3 Modifications to RNAi Therapies Can Enhance Stability and Half-life, and Reduce Off-target Effects211
4.2.4.4 Synthetic siRNAs Are Resistant to Degradation by Serum Nucleases211
4.3 RNA Therapies Are Expected To Create Significant Impact on the Current Therapies After They Enter the Market221
4.3.1 Current Therapies in the Market Are Expected to Witness Strong Competition from RNA Therapies Once They Enter the Market221
4.3.2 RNA Therapies Have Created a Significant Impact on Major Funding Institutions Such As Venture Capitalist Firms and Private Equity Firms221
4.3.3 The Impact of RNA Therapies on Patients Is Expected To Grow Gradually Since Patients Would Switch Over Only After RNA Therapies Pass through Proof-Of-Concept Studies 221
RNA Therapeutics Has Already Made a Significant Impact on Large Pharmaceutical and Biotech Companies231
4.4 Key Challenges Such As Lack of Effective Delivery Systems are Holding Back RNA Therapies from Entering the Market231
5 RNA Therapeutics Market Characterization248
5.1 Market Potential241
Target Sales Volume251
5.3 Annual Cost of Therapy261
Technology Adoption Framework271
5.4.1 RNA Technology has the potential to meet Unmet-needs in Major Diseases271
5.4.1.1 Cancer271
5.4.1.2 Viral Infections271
5.4.2 RNA technology Failed in Proof-of-concept Studies271
5.4.3 Lack of awareness among patients as well as physicians is embracing the adoption of RNA Technology281
5.4.4 RNA therapies, launched till now, failed to pass through proof-of-concept studies281
5.5 RNA Therapeutics Market Drivers 281
5.5.1 Dual Mechanism of Action is the Major Factor Driving RNA Therapeutics Market Potential281
5.5.2 Failure of Conventional Therapies in Curing Chronic Diseases has Created High-unmet Needs291
Major Break-through Technologies in RNA Research and Development Opened-up New Markets301
5.5.4 Increased Funding on RNA Research by Major Countries such as the US and Europe301
5.6 RNA Therapeutics Market Restraints301
5.6.1 Many RNA Therapies are Failing at Phase III Clinical Development301
5.6.2 The Characteristics of RNA Structure make them Vulnerable to Human Enzymes311
5.6.3 Lack of Effective Delivery Technologies That can Deliver RNA therapies to the Target Site are making RNA Therapies Ineffective311
5.6.4 RNA therapies can cause potential side-effects and off-target effects311
6 RNA Therapeutics Market Description328
SWOT Analysis321
6.1.1 RNA Therapies Hold a Competitive Edge over Conventional Therapies Due to Their Gene Silencing Ability 321
6.1.2 Although RNA Therapies Have the Potential to Cure Diseases, Few Drawbacks Such As Instability and Off-targets are Holding Them from Displaying Desired Efficacy Levels 321
6.1.3 Abundant Opportunities in Terms of Unmet Needs Exist for RNA Therapies in Chronic disease Conditions Associated with Genetic Mutations and Protein Overexpression331
6.1.4 Similar to RNA Therapies, Other Treatments such as Stem Cell Therapies Are Also in Research and Development, and These Therapies Can Pose a Threat to RNA Therapeutics Market Potential331
6.2 Porters Five Forces Analysis on RNA Therapeutics331
6.2.1 Threat of Substitutes331
6.2.2 Threat of Potential Entrants341
6.2.3 Bargaining Power of Suppliers341
6.2.4 Bargaining Power of Buyers341
PEST Analysis351
6.3.1 The US351
6.3.1.1 Political Forces351
6.3.1.2 Economic Factors351
Technical Forces361
6.3.1.4 Social Forces361
6.3.2 The Top five Countries in Europe361
6.3.2.1 Political Forces361
6.3.2.2 Economic Factors371
6.3.2.3 Technical Forces371
6.3.2.4 Social Forces371
6.3.3 Japan371
6.3.3.1 Political Forces381
6.3.3.2 Economic Factors381
6.3.3.3 Technical Forces381
6.3.3.4 Social Forces381
6.4 Funding381
6.4.1 US381
6.4.2 Europe391
7 RNA Therapeutics Competitive Landscape4016
7.1 Key Players411
7.1.1 Antisense Pharma GmbH411
7.1.1.1 Trabedersen411
7.1.1.2 AP11014421
7.1.2 Lorus Therapeutics421
7.1.2.1 LOR-2040421
7.1.3 Isis Pharmaceuticals431
7.1.3.1 Mipomersen431
7.1.3.2 Vitravene431
7.1.4 Alfacell Corporation441
7.1.4.1 Onconase441
7.1.5 Genta Incorporated451
7.1.5.1 Genasense451
Atlantic Healthcare461
7.1.6.1 Alicaforsen461
7.1.7 Alnylam461
7.1.8 OPKO501
Bevasiranib511
7.2 Promising Companies Developing RNAi under Collaborations with major Companies511
7.2.1 Oxford BioMedica512
7.2.2 Dicerna Pharmaceuticals531
7.2.3 Silence Therapeutics plc531
7.2.4 Cequent Pharmaceuticals, Inc541
7.2.5 SantarisPharma A/S542
8 RNA Therapeutics R&D Pipeline Analysis5614
8.1 Strategic Pipeline Assessment563
8.2 Profiles of Key Late-Stage Drugs591
8.2.1 Mipomersen591
8.2.1.1 Follow on Indications591
8.2.2 Bevasiranib591
Follow On indication601
8.2.3 LOR-2040601
8.2.3.1 Mechanism of Action601
8.2.3.2 Follow on Indication601
8.2.4 Genasense601
8.2.4.1 Mechanism of Action611
8.2.4.2 Follow on Indication611
8.2.5 Trovax611
8.2.5.1 Mechanism of Action611
8.2.5.2 Follow on Indications611
8.2.6 Trabedersen611
8.2.6.1 Mechanism of Action611
8.2.6.2 Follow on Indications611
Onconase621
8.2.7.1 Mechanism of Action621
8.2.7.2 Follow on Indications621
8.2.8 Alicaforsen621
8.2.8.1 Mechanism of Action 621
8.2.8.2 Follow on Indication621
8.3 Insights into Most Promising Drugs631
8.3.1 Mipomersen631
8.3.1.1 Follow on Indications631
8.3.1.2 Clinical Studies631
8.3.2 LOR-2040631
Mechanism of Action641
8.3.2.2 Follow on Indication641
8.3.2.3 Clinical Studies641
8.3.3 Genasense641
8.3.3.1 Mechanism of Actions651
8.3.3.2 Follow on Indication651
8.3.3.3 Clinical Studies651
8.3.4 ProSavin651
8.3.4.1 Clinical Studies651
Trovax661
8.3.5.1 Mechanism of Action661
8.3.5.2 Follow on Indication661
8.3.5.3 Clinical Studies661
8.3.6 Trabedersen661
8.3.6.1 Mechanism of Action671
8.3.6.2 Follow on Indications671
8.3.6.3 Clinical Studies671
8.3.7 Onconase671
8.3.7.1 Mechanism of Action671
8.3.7.2 Follow on Indications681
8.3.7.3 Clinical Studies681
8.3.8 Alicaforsen681
8.3.8.1 Mechanism of Action 681
8.3.8.2 Follow on Indication681
8.3.8.3 Clinical Studies691
RNA Therapeutics M&A Landscape7013
9.1 Big Pharmaceutical Companies Relentlessly Attempting to Unlock RNA therapy Potential701
Influx of Huge Venture Capitalist Funding into Small and Medium Biotech Companies Venturing into RNA Therapeutics Development711
9.2.1 Dicerna Pharmaceuticals711
9.2.2 Cequent Pharmaceuticals711
9.2.3 Prosensa711
9.2.4 Cylene Pharmaceuticals711
9.3 High Value Collaborations involving RNA Therapies711
9.3.1 ISIS Pharmaceuticals711
9.3.2 Alnylam 721
9.3.3 Silence Therapeutics and AstraZeneca721
9.3.4 Santaris Pharma and Wyeth Pharmaceuticals721
9.4 Large Pharmaceutical and Biotechnology companies are vying for major acquisitions in the RNA Therapeutics Market 721
9.4.1 Thermo Fisher Scientific and Open Biosystems721
9.4.2 Roche and Mirus Bio721
R&D Licensing Agreements731
9.5.1 Deals by Phase731
9.5.2 Deals by Geography731
9.5.3 Deals by Licensing Type741
9.5.4 Deals by Value ($)751
9.5.5 Discovery/Development751
9.5.5.1 GlaxoSmithKline (GSK) and Prosensa Alliance Worth $680 million751
9.5.5.2 Alnylam Pharmaceuticals, Inc. with Isis Pharmaceuticals, Inc751
Alnylam Pharmaceuticals, Inc with Takeda Pharmaceutical Company Limited761
9.5.5.4 Alnylam Pharmaceuticals, Inc with GlaxoSmithKline (GSK)761
9.5.5.5 Archemix Corporation with Eli Lilly and Company761
9.5.5.6 Archemix Corporation with GlaxosmithKline (GSK)761
9.5.5.7 PTC Therapeutics with Roche761
9.5.5.8 PTC Therapeutics with Schering-Plough Corporation771
9.5.5.9 Santaris Pharma A/S with Shire plc771
9.5.5.10 Tekmira with Roche771
9.5.5.11 Tekmira with Bristol-Myers Squibb Company773
9.5.6 Preclinical801
9.5.6.1 Novosom AG with Isis Pharmaceuticals:801
9.5.7 Phase I811
9.5.8 Phase II811
9.5.8.1 Cubist Pharmaceuticals, Inc. with Alnylam Pharmaceuticals, Inc:811
9.5.9 Phase III821
9.5.9.1 Alfacell Corporation with Strativa Pharmaceuticals821
10 RNA Therapeutics: Appendix837
10.1 Market Definitions831
10.2 Abbreviations831
10.3 Research Methodology845
10.3.1 Coverage 851
10.3.2 Secondary Research851
10.3.3 Primary Research861
10.3.4 Forecasts861
10.3.4.1 Epidemiology-based Forecasting862
10.3.5 Expert Panel Validation881
10.4 Contact Us891
10.5 Disclaimer891
10.6 Sources891

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma" Feb 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Ribonucleic-Acid-RNA-Therapeutics-Strong-Potential-to-Address-Unmet-Needs-in-Pharma-2115-22>
  
APA:
GBI Research Reports. (2010). Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma Feb 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Ribonucleic-Acid-RNA-Therapeutics-Strong-Potential-to-Address-Unmet-Needs-in-Pharma-2115-22>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.